Gamma Diagnostics awarded a grant to develop Antisense Oligonucleotides
Gamma Diagnostics has been awarded $277,710 USD by the National Institutes of Health to develop Antisense Oligonucleotides to Regulate Gamma Prime Fibrinogen Levels
Afri Grow Partners with Gamma Diagnostics
We are thrilled to announce an exclusive distribution agreement and the SAHPRA approval of GammaCoeur™ CVD Risk ELISA Test System with Afri Grow (Pty) Ltd.
New publication of GPF as a biomarker of Covid-19
Gamma Diagnostics is excited to announce that our study γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity has been published in Blood Cells, Molecules and Diseases.
Gamma Diagnostics and OHSU Announce a Licensing Agreement
Gamma Diagnostics Inc. (GDx) and Oregon Health & Science University (OHSU) have signed a licensing agreement that seeks to further develop and commercially promote the use of Gamma Prime Fibrinogen (GPF) as an inflammatory and clotting risk biomarker.
What is Gamma Prime Fibrinogen?
Dr. David Farrell shares his poster and abstract at the American Heart Association meeting. COVID-19 patients can develop extremely high levels of gamma prime fibrinogen (GPF).
Why isn't heparin effective in severe COVID-19 thrombosis?
Stay tuned for an exciting Covid-19 study and a newly identified thrombosis biomarker to be presented at the American Heart Association meeting.
Gamma Diagnostics Joins Expert Dojo's Healthcare Cohort
We are happy to announce Gamma Diagnostics joined Expert DOJO's September 2021 healthcare accelerator program.